Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

PHASE2CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

November 29, 2024

Study Completion Date

November 29, 2024

Conditions
Advanced Soft Tissue Sarcoma
Interventions
DRUG

Standard arm: Trabectedin in monotherapy

Trabectedin in monotherapy

DRUG

Experimental arm: Trabectedin + Olaparib

Trabectedin given in combination to olaparib

Trial Locations (13)

10060

Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

20141

Istituto Europeo di Oncologia, Milan

33081

Centro di Riferimento Oncologico di Aviano, Aviano

40136

Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors, Bologna

40139

Azienda Ospedaliero-Universitaria Di Bologna, Bologna

59100

Nuovo Ospedale di Prato, Prato

90127

Azienda Ospedaliera Universitaria Paolo Giaccone, Palermo

Unknown

I.R.S.T. di Meldola, Meldola

Ospedale San Giovanni Bosco, Torino

Irccs Istituto Oncologico Veneto (Iov), Padua

00128

Policlinico Universitario Campus Biomedico, Roma

00144

Istituto Nazionale Tumori Regina Elena - Unit of Medical Oncology I, Roma

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

PharmaMar

INDUSTRY

collaborator

AstraZeneca

INDUSTRY

lead

Italian Sarcoma Group

NETWORK